Colrain Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Colrain Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,696	Closed	-$683K	–	27
2024 Q4	$683K	Buy	+1,696	New	+$786K	0.67%	23
2022 Q3	$2.9M	Hold	10,000	–	–	4.83%	7
2022 Q2	$2.82M	Hold	10,000	–	–	4.41%	8
2022 Q1	$2.61M	Hold	10,000	–	–	3.64%	15
2021 Q4	$2.2M	Buy	10,000 +1,700	+20%	+$331K	2.64%	17
2021 Q3	$1.5M	Hold	8,300	–	–	2.82%	17
2021 Q2	$1.67M	Buy	+8,300	New	+$1.74M	3.01%	17

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Colrain Capital's VRTX Position: Q1 2025 in Review

Colrain Capital sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 1,696 shares — an estimated $683K sold.

Colrain Capital first reported a position in VRTX in Q2 2021 and held it in 7 quarters. The position peaked at $2.9M in Q3 2022. 1,612 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

Colrain Capital reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Colrain Capital sold 1,696 Vertex Pharmaceuticals shares in Q1 2025, an estimated $683K.
Colrain Capital first reported a position in Vertex Pharmaceuticals in Q2 2021 and held it in 7 quarters.
Colrain Capital's Vertex Pharmaceuticals position peaked at $2.9M in Q3 2022.
1,612 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Colrain Capital's 13F filing for Q1 2025, filed 12 May 2025.